论文部分内容阅读
目的 :探讨益肝康对实验性肝纤维化大鼠肝细胞损伤的保护作用。方法 :采用 4 0 % CCl4 皮下注射制备大鼠实验性肝纤维化模型 ,与秋水仙碱对照 ,观察益肝康对肝功能、肝脏组织病理变化和超微结构变化的影响。结果 :益肝康能明显改善实验性肝纤维化大鼠的肝功能 ,提高血清白蛋白 (Alb)、减轻肝细胞脂肪变性和坏死。血清丙氨酸转氨酶 (AL T)、Alb和血清球蛋白 (Glb)的变化 ,与对照组比较差异有显著性意义 (分别为 P <0 .0 1,P <0 .0 5 ,P <0 .0 5 )。益肝康组大鼠肝组织的脂肪变性程度较秋水仙碱组明显减轻 ,脂肪变性积分分别为 2 .0 0± 1.36和 2 .75± 0 .6 5 (P <0 .0 5 ) ;电镜观察表明益肝康对实验性肝纤维化大鼠肝细胞线粒体等细胞器的损伤具有保护作用。结论 :益肝康对 CCl4 损伤性肝细胞有保护作用 ,可改善肝功能 ,对线粒体等细胞器的损伤具有保护作用
Objective: To investigate the protective effect of Yigankang on hepatocyte injury in experimental liver fibrosis rats. METHODS: The experimental hepatic fibrosis model was established by subcutaneous injection of 40% CCl4. Compared with colchicine, the effects of Yigankang on hepatic function, liver pathological changes and ultrastructural changes were observed. Results: Yigankang could significantly improve the liver function of experimental liver fibrosis rats, increase serum albumin (Alb), and reduce liver cell steatosis and necrosis. The changes of serum alanine aminotransferase (AL T), Alb, and serum globulin (Glb) were significantly different from those in the control group (P <0. 01, P <0. 05, P <0, respectively). .0 5 ). The liver steatosis in Yigankang group was significantly less than that in colchicine group. The steatosis scores were 2.0 ± 1.36 and 2.75 ± 0.65, respectively (P <0.05). Observations showed that Yigankang had protective effects on hepatocyte mitochondria and other organelles in rats with experimental hepatic fibrosis. Conclusion: Yigankang has a protective effect on CCl4 damaged hepatocytes, which can improve liver function and protect mitochondria and other organelles from injury.